CRVS
Corvus Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$14.39
−1.77%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 55.0K | 105.0K | — | — | — |
| Gross Profit | (55.0K) | (105.0K) | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 45.5M | 33.7M | 19.4M | 16.5M | 24.5M |
| SG&A Expense | 11.4M | 9.3M | 8.2M | 6.9M | 8.1M |
| General & Admin Expense | 11.4M | 9.3M | 8.2M | 6.9M | 8.1M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | (105.0K) | — | — | — |
| Total Operating Expenses | 56.9M | 42.9M | 27.5M | 23.4M | 32.6M |
| Cost and Expenses | 57.0M | 43.0M | 27.5M | 23.4M | 32.6M |
| Operating Income (EBIT) | (57.0M) | (43.0M) | (27.5M) | (23.4M) | (32.6M) |
| Non-Operating | |||||
| Interest Income | (1.2M) | 2.5M | 1.8M | 1.6M | 654.0K |
| Interest Expense | 1.8M | — | — | — | — |
| Net Interest Income | (2.9M) | 2.5M | 1.8M | 1.6M | 654.0K |
| Other Non-Op Income/Expense | 3.5M | 27.7M | (34.7M) | (3.6M) | (8.7M) |
| Non-Operating Income (excl Interest) | (5.3M) | (27.7M) | 34.7M | 3.6M | 8.7M |
| EBT (Pre-Tax Income) | (53.4M) | (15.3M) | (62.3M) | (27.0M) | (41.3M) |
| Income Tax Expense | 709.0K | — | — | — | — |
| Bottom Line | |||||
| Net Income | (54.1M) | (15.3M) | (62.3M) | (27.0M) | (41.3M) |
| Earnings from Cont. Ops | (54.1M) | (15.3M) | (62.3M) | (27.0M) | (41.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (54.1M) | (42.4M) | (62.3M) | (27.0M) | (41.3M) |
| Per Share | |||||
| Basic EPS | ($0.64) | ($0.19) | ($1.02) | ($0.56) | ($0.89) |
| Diluted EPS | ($0.64) | ($0.53) | ($1.02) | ($0.56) | ($0.89) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 92.4M | 79.0M | 61.0M | 48.0M | 46.6M |
| Diluted Shares Outstanding | 92.4M | 79.7M | 61.0M | 48.0M | 46.6M |
| Profitability Metrics | |||||
| EBITDA | (51.5M) | (15.2M) | (62.2M) | (26.9M) | (40.9M) |
| D&A | 146.0K | 105.0K | 85.0K | 151.0K | 367.0K |
| EBIT | (51.6M) | (15.3M) | (62.3M) | (27.0M) | (41.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026